IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY (IGAN) explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY (IGAN) trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY (IGAN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug trial offers hope for kidney disease patients
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 30 Chinese adults with kidney diseases caused by the immune system attacking the kidneys. The goal is to see if the drug is safe and can help control the disease. Some participants will get ADX-038 alone, and others will get it with a…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 08:54 UTC
-
New drug zigakibart aims to slow kidney damage in IgA nephropathy patients
Disease control Recruiting nowThis study tests a new drug called zigakibart in 32 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug can slow down the disease by measuring changes in kidney tissue and other markers. Participants must have a confirmed diagnosis and persistent protein…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 08:34 UTC
-
New drug aims to protect kidneys in common autoimmune disease
Disease control Recruiting nowThis study tests a drug called felzartamab in people with IgA nephropathy, a kidney disease where abnormal antibodies build up and damage the kidneys. The goal is to see if felzartamab can reduce protein in the urine, a sign of kidney damage. About 454 adults with protein in thei…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated May 22, 2026 13:54 UTC